Hop (Humulus lupulus L.), as a key ingredient for beer brewing, is also a source of many biologically active molecules. A notable compound, 8-prenylnaringenin (8-PN), structurally belonging to the group of prenylated flavonoids, was shown to be a potent phytoestrogen, and thus, became the topic of active research. Here, we overview the pharmacological properties of 8-PN and its therapeutic opportunities. Due to its estrogenic effects, administration of 8-PN represents a novel therapeutic approach to the treatment of menopausal and post-menopausal symptoms that occur as a consequence of a progressive decline in hormone levels in women. Application of 8-PN in the treatment of menopause has been clinically examined with promising results. Other activities that have already been assessed include the potential to prevent bone-resorption or inhibition of tumor growth. On the other hand, the use of phytoestrogens is frequently questioned regarding possible adverse effects associated with long-term consumption. In conclusion, we emphasize the implications of using 8-PN in future treatments of menopausal and post-menopausal symptoms, including the need for precise evidence and further investigations to define the safety risks related to its therapeutic use.

Department of Biotechnology University of Chemistry and Technology Prague Technická 5 166 28 Prague 6 Czech Republic

Zobrazit více v PubMed

Zanoli P., Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. J. Ethnopharmacol. 2008;116:383–396. doi: 10.1016/j.jep.2008.01.011. PubMed DOI

Karabin M., Hudcova T., Jelinek L., Dostalek P. Biologically active compounds from hops and prospects for their use. Compr. Rev. Food Sci. Food Saf. 2016;15:542–567. doi: 10.1111/1541-4337.12201. PubMed DOI

Poluzzi E., Piccinni C., Raschi E., Rampa A., Recanatini M., De Ponti F. Phytoestrogens in postmenopause: The state of the art from a chemical, pharmacological and regulatory perspective. Curr. Med. Chem. 2014;21:417–436. doi: 10.2174/09298673113206660297. PubMed DOI PMC

Bartmanska A., Tronina T., Poplonski J., Huszcza E. Biotransformations of prenylated hop flavonoids for drug discovery and production. Curr. Drug Metab. 2013;14:1083–1097. doi: 10.2174/1389200214666131211151855. PubMed DOI

Chadwick L., Pauli G., Farnsworth N. The pharmacognosy of Humulus lupulus L. (hops) with an emphasis on estrogenic properties. Phytomedicine. 2006;13:119–131. doi: 10.1016/j.phymed.2004.07.006. PubMed DOI PMC

Bolego C., Poli A., Cignarella A., Paoletti R. Phytoestrogens: Pharmacological and therapeutic perspectives. Curr. Drug Targets. 2003;4:77–87. doi: 10.2174/1389450033347000. PubMed DOI

Ososki A.L., Kennelly E.J. Phytoestrogens: A review of the present state of research. Phytother. Res. 2003;17:845–869. doi: 10.1002/ptr.1364. PubMed DOI

Terao J., Mukai R. Prenylation modulates the bioavailability and bioaccumulation of dietary flavonoids. Arch. Biochem. Biophys. 2014;559:12–16. doi: 10.1016/j.abb.2014.04.002. PubMed DOI

Ohn Mar S., Malhi F.S., Syed Rahim S.H., Soe M.M. Chinese and Indian women's experience with alternative medications for menopause related symptoms: A qualitative analysis. Chin. J. Integr. Med. 2017:1–7. doi: 10.1007/s11655-017-2780-6. PubMed DOI

Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., Wallace R.B., Jackson R.D., Pettinger M.B., Ridker P.M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the women's health initiative observational study. JAMA. 2002;288:980–987. doi: 10.1001/jama.288.8.980. PubMed DOI

Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., Ko M., LaCroix A.Z., Margolis K.L., Stefanick M.L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477. doi: 10.1001/jama.297.13.1465. PubMed DOI

Folsom A.R., Anderson J.P., Ross J.A. Estrogen replacement therapy and ovarian cancer. Epidemiology. 2004;15:100–104. doi: 10.1097/01.ede.0000091606.31903.8e. PubMed DOI

Heyerick A., Vervarcke S., Depypere H., Bracke M., De Keukeleire D. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas. 2006;54:164–175. doi: 10.1016/j.maturitas.2005.10.005. PubMed DOI

Aghamiri V., Mirghafourvand M., Mohammad-Alizadeh-Charandabi S., Nazemiyeh H. The effect of hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial. Complement. Ther. Clin. Pract. 2016;23:130–135. doi: 10.1016/j.ctcp.2015.05.001. PubMed DOI

Erkkola R., Vervarcke S., Vansteelandt S., Rompotti P., De Keukeleire D., Heyerick A. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine. 2010;17:389–396. doi: 10.1016/j.phymed.2010.01.007. PubMed DOI

Van Duursen M.B., Smeets E.E., Rijk J.C., Nijmeijer S.M., van den Berg M. Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model. Toxicol. Appl. Pharmacol. 2013;269:132–140. doi: 10.1016/j.taap.2013.03.014. PubMed DOI

Venturelli S., Burkard M., Biendl M., Lauer U.M., Frank J., Busch C. Prenylated chalcones and flavonoids for the prevention and treatment of cancer. Nutrition. 2016;32:1171–1178. doi: 10.1016/j.nut.2016.03.020. PubMed DOI

Stompor M., Uram L., Podgorski R. In vitro effect of 8-prenylnaringenin and naringenin on fibroblasts and glioblastoma cells-cellular accumulation and cytotoxicity. Molecules. 2017;22:1092. doi: 10.3390/molecules22071092. PubMed DOI PMC

Seo H.S., Choi H.S., Choi H.S., Choi Y.K., Um J.Y., Choi I., Shin Y.C., Ko S.G. Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-κB signaling in HER2-overexpressing breast cancer cells. Anticancer Res. 2011;31:3301–3313. PubMed

Busch C., Noor S., Leischner C., Burkard M., Lauer U.M., Venturelli S. Anti-proliferative activity of hop-derived prenylflavonoids against human cancer cell lines. Wien. Med. Wochenschr. 2015;165:258–261. doi: 10.1007/s10354-015-0355-8. PubMed DOI

Keiler A.M., Helle J., Bader M.I., Ehrhardt T., Nestler K., Kretzschmar G., Bernhardt R., Vollmer G., Nikolic D., Bolton J.L., et al. A standardized Humulus lupulus (L.) ethanol extract partially prevents ovariectomy-induced bone loss in the rat without induction of adverse effects in the uterus. Phytomedicine. 2017;34:50–58. doi: 10.1016/j.phymed.2017.08.001. PubMed DOI PMC

Żołnierczyk A.K., Mączka W.K., Grabarczyk M., Wińska K., Woźniak E., Anioł M. Isoxanthohumol—Biologically active hop flavonoid. Fitoterapia. 2015;103:71–82. doi: 10.1016/j.fitote.2015.03.007. PubMed DOI

Karabin M., Hudcova T., Jelinek L., Dostalek P. Biotransformations and biological activities of hop flavonoids. Biotechnol. Adv. 2015;33:1063–1090. doi: 10.1016/j.biotechadv.2015.02.009. PubMed DOI

Karabin M., Hudcova T. Význam chmelových prenylflavonoidů pro lidské zdraví. Chem. Listy. 2012;106:1095–1103.

Nikolic D., van Breemen R.B. Analytical methods for quantitation of prenylated flavonoids from hops. Curr. Anal. Chem. 2013;9:71–85. doi: 10.2174/157341113804486554. PubMed DOI PMC

Stevens J.F., Taylor A.W., Deinzer M.L. Quantitative analysis of xanthohumol and related prenylflavonoids in hops and beer by liquid chromatography–tandem mass spectrometry. J. Chromatogr. A. 1999;832:97–107. doi: 10.1016/S0021-9673(98)01001-2. PubMed DOI

Yang X., Jiang Y., Yang J., He J., Sun J., Chen F., Zhang M., Yang B. Prenylated flavonoids, promising nutraceuticals with impressive biological activities. Trends Food Sci. Technol. 2015;44:93–104. doi: 10.1016/j.tifs.2015.03.007. DOI

Milligan S.R. Reproductive and estrogenic effects of 8-prenylnaringenin in hops. In: Preedy V.R., editor. Beer in Health and Disease Prevention. Elsevier; San Diego, CA, USA: 2008. pp. 711–723.

Koch W., Heim G. Estrogens in hops and beer; preliminary report. Munch. Med. Wochenschr. 1953;95:845. PubMed

Milligan S., Kalita J., Heyerick A., Rong H., De Cooman L., De Keukeleire D. Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. J. Clin. Endocrinol. Metab. 1999;84:2249. doi: 10.1210/jcem.84.6.5887. PubMed DOI

Rietjens I.M., Louisse J., Beekmann K. The potential health effects of dietary phytoestrogens. Br. J. Pharmacol. 2017;174:1263–1280. doi: 10.1111/bph.13622. PubMed DOI PMC

Mueller S.O. Overview of in vitro tools to assess the estrogenic and antiestrogenic activity of phytoestrogens. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2002;777:155–165. doi: 10.1016/S1570-0232(02)00282-9. PubMed DOI

Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. Production and actions of estrogens. N. Engl. J. Med. 2002;346:340–352. doi: 10.1056/NEJMra000471. PubMed DOI

Farzaneh S., Zarghi A. Estrogen receptor ligands: A review (2013–2015) Sci. Pharm. 2016;84:409. doi: 10.3390/scipharm84030409. PubMed DOI PMC

Simons R., Gruppen H., Bovee T.F., Verbruggen M.A., Vincken J.-P. Prenylated isoflavonoids from plants as selective estrogen receptor modulators (phytoSERMs) Food Funct. 2012;3:810–827. doi: 10.1039/c2fo10290k. PubMed DOI

Stevens J.F., Page J.E. Xanthohumol and related prenylflavonoids from hops and beer: To your good health! Phytochemistry. 2004;65:1317–1330. doi: 10.1016/j.phytochem.2004.04.025. PubMed DOI

Hirsch H.D., Shih E., Thacker H.L. ERAAs for menopause treatment: Welcome the ‘designer estrogens’. Clevel. Clin. J. Med. 2017;84:463–470. doi: 10.3949/ccjm.84a.15140. PubMed DOI

Hadji P. The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric. 2012;15:513–523. doi: 10.3109/13697137.2012.688079. PubMed DOI PMC

Harris D., Besselink E., Henning S., Go V., Heber D. Phytoestrogens induce differential estrogen receptor alpha-or beta-mediated responses in transfected breast cancer cells. Exp. Biol. Med. 2005;230:558–568. doi: 10.1177/153537020523000807. PubMed DOI

Roelens F., Heldring N., Dhooge W., Bengtsson M., Comhaire F., Gustafsson J.A., Treuter E., De Keukeleire D. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors α and β. J. Med. Chem. 2006;49:7357–7365. doi: 10.1021/jm060692n. PubMed DOI

Kretzschmar G., Zierau O., Wober J., Tischer S., Metz P., Vollmer G. Prenylation has a compound specific effect on the estrogenicity of naringenin and genistein. J. Steroid Biochem. Mol. Biol. 2010;118:1–6. doi: 10.1016/j.jsbmb.2009.08.005. PubMed DOI

Mukai R. Prenylation enhances the biological activity of dietary flavonoids by altering their bioavailability. Biosci. Biotechnol. Biochem. 2018;82:207–215. doi: 10.1080/09168451.2017.1415750. PubMed DOI

Tan K.W., Cooney J., Jensen D., Li Y., Paxton J.W., Birch N.P., Scheepens A. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2) Mol. Nutr. Food Res. 2014;58:2099–2110. doi: 10.1002/mnfr.201400288. PubMed DOI

Rad M., Hümpel M., Schaefer O., Schoemaker R., Schleuning W.D., Cohen A., Burggraaf J. Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. Br. J. Clin. Pharmacol. 2006;62:288–296. doi: 10.1111/j.1365-2125.2006.02656.x. PubMed DOI PMC

O’Connell M.B. Pharmacokinetic and pharmacologic variation between different estrogen products. J. Clin. Pharmacol. 1995;35:18S–24S. doi: 10.1002/j.1552-4604.1995.tb04143.x. PubMed DOI

Calvo-Castro L.A., Burkard M., Sus N., Scheubeck G., Leischner C., Lauer U.M., Bosy-Westphal A., Hund V., Busch C., Venturelli S. The oral bioavailability of 8-prenylnaringenin from hops (Humulus lupulus L.) in healthy women and men is significantly higher than that of its positional isomer 6-prenylnaringenin in a randomized crossover trial. Mol. Nutr. Food Res. 2018 doi: 10.1002/mnfr.201700838. PubMed DOI

Van Breemen R.B., Yuan Y., Banuvar S., Shulman L.P., Qiu X., Alvarenga R.F.R., Chen S.N., Dietz B.M., Bolton J.L., Pauli G.F. Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops. Mol. Nutr. Food Res. 2014;58:1962–1969. doi: 10.1002/mnfr.201400245. PubMed DOI PMC

Nikolic D., Li Y., Chadwick L.R., Grubjesic S., Schwab P., Metz P., Van Breemen R.B. Metabolism of 8-prenylnaringenin, a potent phytoestrogen from hops (Humulus lupulus), by human liver microsomes. Drug Metab. Dispos. 2004;32:272–279. doi: 10.1124/dmd.32.2.272. PubMed DOI

Kim H.J., Kim S.-H., Kang B.Y., Lee I.-S. Microbial metabolites of 8-prenylnaringenin, an estrogenic prenylflavanone. Arch. Pharm. Res. 2008;31:1241–1246. doi: 10.1007/s12272-001-2102-5. PubMed DOI

Possemiers S., Bolca S., Grootaert C., Heyerick A., Decroos K., Dhooge W., De Keukeleire D., Rabot S., Verstraete W., Van de Wiele T. The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J. Nutr. 2006;136:1862–1867. doi: 10.1093/jn/136.7.1862. PubMed DOI

Abdi F., Mobedi H., Roozbeh N. Hops for menopausal vasomotor symptoms: Mechanisms of action. J. Menopausal Med. 2016;22:62–64. doi: 10.6118/jmm.2016.22.2.62. PubMed DOI PMC

Sandoval-Ramírez B.A., Lamuela-Raventós R.M., Estruch R., Sasot G., Doménech M., Tresserra-Rimbau A. Beer polyphenols and menopause: Effects and mechanisms—A review of current knowledge. Oxid. Med. Cell. Longev. 2017;2017:4749131. doi: 10.1155/2017/4749131. PubMed DOI PMC

Moore T.R., Franks R.B., Fox C. Review of efficacy of complementary and alternative medicine treatments for menopausal symptoms. J. Midwifery Womens Health. 2017;62:286–297. doi: 10.1111/jmwh.12628. PubMed DOI

Abdi F., Mobedi H., Mosaffa N., Dolatian M., Ramezani Tehrani F. Hormone therapy for relieving postmenopausal vasomotor symptoms: A systematic review. Arch. Iran. Med. 2016;19:141–146. PubMed

Miller V.M., Harman S.M. An update on hormone therapy in postmenopausal women: Mini-review for the basic scientist. Am. J. Physiol. Heart Circ. Physiol. 2017;313:H1013–H1021. doi: 10.1152/ajpheart.00383.2017. PubMed DOI PMC

Langer R.D. The evidence base for HRT: What can we believe? Climacteric. 2017;20:91–96. doi: 10.1080/13697137.2017.1280251. PubMed DOI

Lobo R.A., Pickar J.H., Stevenson J.C., Mack W.J., Hodis H.N. Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 2016;254:282–290. doi: 10.1016/j.atherosclerosis.2016.10.005. PubMed DOI

Taylor M. Complementary and alternative approaches to menopause. Endocrinol. Metab. Clin. N. Am. 2015;44:619–648. doi: 10.1016/j.ecl.2015.05.008. PubMed DOI

Tonob D., Melby M.K. Broadening our perspectives on complementary and alternative medicine for menopause: A narrative review. Maturitas. 2017;99:79–85. doi: 10.1016/j.maturitas.2017.01.013. PubMed DOI

Locklear T.D., Doyle B.J., Perez A.L., Wicks S.M., Mahady G.B. Menopause in Latin America: Symptoms, attitudes, treatments and future directions in Costa Rica. Maturitas. 2017;104:84–89. doi: 10.1016/j.maturitas.2017.07.008. PubMed DOI PMC

Depypere H.T., Comhaire F.H. Herbal preparations for the menopause: Beyond isoflavones and black cohosh. Maturitas. 2014;77:191–194. doi: 10.1016/j.maturitas.2013.11.001. PubMed DOI

Bowe J., Li X.F., Kinsey-Jones J., Heyerick A., Brain S., Milligan S., O’Byrne K. The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes. J. Endocrinol. 2006;191:399–405. doi: 10.1677/joe.1.06919. PubMed DOI PMC

Heinemann L.A., Potthoff P., Schneider H.P. International versions of the menopause rating scale (MRS) Health Qual. Life Outcomes. 2003;1:28. doi: 10.1186/1477-7525-1-28. PubMed DOI PMC

Keiler A.M., Zierau O., Kretzschmar G. Hop extracts and hop substances in treatment of menopausal complaints. Planta Med. 2013;79:576–579. doi: 10.1055/s-0032-1328330. PubMed DOI

Effenberger K.E., Johnsen S.A., Monroe D.G., Spelsberg T.C., Westendorf J.J. Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J. Steroid Biochem. Mol. Biol. 2005;96:387–399. doi: 10.1016/j.jsbmb.2005.04.038. PubMed DOI

Humpel M., Isaksson P., Schaefer O., Kaufmann U., Ciana P., Maggi A., Schleuning W.D. Tissue specificity of 8-prenylnaringenin: Protection from ovariectomy induced bone loss with minimal trophic effects on the uterus. J. Steroid Biochem. Mol. Biol. 2005;97:299–305. doi: 10.1016/j.jsbmb.2005.05.009. PubMed DOI

Ming L.G., Lv X., Ma X.N., Ge B.F., Zhen P., Song P., Zhou J., Ma H.P., Xian C.J., Chen K.M. The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro. Endocrinology. 2013;154:1202–1214. doi: 10.1210/en.2012-2086. PubMed DOI

Luo D., Kang L., Ma Y., Chen H., Kuang H., Huang Q., He M., Peng W. Effects and mechanisms of 8-prenylnaringenin on osteoblast MC3T3-E1 and osteoclast-like cells RAW264.7. Food Sci. Nutr. 2014;2:341–350. doi: 10.1002/fsn3.109. PubMed DOI PMC

Hemachandra L., Madhubhani P., Chandrasena R., Esala P., Chen S.-N., Main M., Lankin D.C., Scism R.A., Dietz B.M., Pauli G.F. Hops (Humulus lupulus) inhibits oxidative estrogen metabolism and estrogen-induced malignant transformation in human mammary epithelial cells (MCF-10A) Cancer Prev. Res. 2012;5:73–81. doi: 10.1158/1940-6207.CAPR-11-0348. PubMed DOI PMC

Wang S., Dunlap T.L., Howell C.E., Mbachu O.C., Rue E.A., Phansalkar R., Chen S.N., Pauli G.F., Dietz B.M., Bolton J.L. Hop (Humulus lupulus L.) extract and 6-prenylnaringenin induce P450 1A1 catalyzed estrogen 2-hydroxylation. Chem. Res. Toxicol. 2016;29:1142–1150. doi: 10.1021/acs.chemrestox.6b00112. PubMed DOI PMC

Costa R., Rodrigues I., Guardao L., Rocha-Rodrigues S., Silva C., Magalhaes J., Ferreira-de-Almeida M., Negrao R., Soares R. Xanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice. J. Nutr. Biochem. 2017;45:39–47. doi: 10.1016/j.jnutbio.2017.03.006. PubMed DOI

Fugh-Berman A. “Bust enhancing” herbal products. Obstet. Gynecol. 2003;101:1345–1349. PubMed

Di Vito C., Bertoni A., Nalin M., Sampietro S., Zanfa M., Sinigaglia F. The phytoestrogen 8-prenylnaringenin inhibits agonist-dependent activation of human platelets. Biochim. Biophys. Acta Gen. Subj. 2012;1820:1724–1733. doi: 10.1016/j.bbagen.2012.06.018. PubMed DOI

Myasoedova V.A., Kirichenko T.V., Melnichenko A.A., Orekhova V.A., Ravani A., Poggio P., Sobenin I.A., Bobryshev Y.V., Orekhov A.N. Anti-atherosclerotic effects of a phytoestrogen-rich herbal preparation in postmenopausal women. Int. J. Mol. Sci. 2016;17:1318. doi: 10.3390/ijms17081318. PubMed DOI PMC

De Cremoux P., This P., Leclercq G., Jacquot Y. Controversies concerning the use of phytoestrogens in menopause management: Bioavailability and metabolism. Maturitas. 2010;65:334–339. doi: 10.1016/j.maturitas.2009.12.019. PubMed DOI

Leclercq G., De Cremoux P., This P., Jacquot Y. Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes. Maturitas. 2011;68:56–64. doi: 10.1016/j.maturitas.2010.10.003. PubMed DOI

Keiler A.M., Dorfelt P., Chatterjee N., Helle J., Bader M.I., Vollmer G., Kretzschmar G., Kuhlee F., Thieme D., Zierau O. Assessment of the effects of naringenin-type flavanones in uterus and vagina. J. Steroid Biochem. Mol. Biol. 2015;145:49–57. doi: 10.1016/j.jsbmb.2014.10.001. PubMed DOI

Helle J., Kraker K., Bader M.I., Keiler A.M., Zierau O., Vollmer G., Welsh J., Kretzschmar G. Assessment of the proliferative capacity of the flavanones 8-prenylnaringenin, 6-(1.1-dimethylallyl)naringenin and naringenin in MCF-7 cells and the rat mammary gland. Mol. Cell. Endocrinol. 2014;392:125–135. doi: 10.1016/j.mce.2014.05.014. PubMed DOI

Keiler A.M., Macejova D., Dietz B.M., Bolton J.L., Pauli G.F., Chen S.N., van Breemen R.B., Nikolic D., Goerl F., Muders M.H., et al. Evaluation of estrogenic potency of a standardized hops extract on mammary gland biology and on MNU-induced mammary tumor growth in rats. J. Steroid Biochem. Mol. Biol. 2017:234–241. doi: 10.1016/j.jsbmb.2017.09.020. PubMed DOI PMC

Bolca S., Li J., Nikolic D., Roche N., Blondeel P., Possemiers S., De Keukeleire D., Bracke M., Heyerick A., Van Breemen R.B. Disposition of hop prenylflavonoids in human breast tissue. Mol. Nutr. Food Res. 2010;54:S284–S294. doi: 10.1002/mnfr.200900519. PubMed DOI PMC

Leclercq G., Jacquot Y. Interactions of isoflavones and other plant derived estrogens with estrogen receptors for prevention and treatment of breast cancer-considerations concerning related efficacy and safety. J. Steroid Biochem. Mol. Biol. 2014;139:237–244. doi: 10.1016/j.jsbmb.2012.12.010. PubMed DOI

Van Duursen M.B. Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women’s health. Toxicol. Res. 2017;6:772–794. doi: 10.1039/C7TX00184C. PubMed DOI PMC

Dietz B.M., Hajirahimkhan A., Dunlap T.L., Bolton J.L. Botanicals and their bioactive phytochemicals for women’s health. Pharmacol. Rev. 2016;68:1026–1073. doi: 10.1124/pr.115.010843. PubMed DOI PMC

Solak K.A., Santos R.R., van den Berg M., Blaauboer B.J., Roelen B.A., van Duursen M.B. Naringenin (NAR) and 8-prenylnaringenin (8-PN) reduce the developmental competence of porcine oocytes in vitro. Reprod. Toxicol. 2014;49:1–11. doi: 10.1016/j.reprotox.2014.05.013. PubMed DOI

Yuan Y., Qiu X., Nikolic D., Chen S.N., Huang K., Li G., Pauli G.F., van Breemen R.B. Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur. J. Pharm. Sci. 2014;53:55–61. doi: 10.1016/j.ejps.2013.12.003. PubMed DOI PMC

Lynch T., Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Phys. 2007;76:391–396. PubMed

Preparation of Hop Estrogen-Active Material for Production of Food Supplements